CureVac (NASDAQ:CVAC) Shares Down 5.8% – Time to Sell?

CureVac (NASDAQ:CVAC) dropped 5.8% during trading on Monday . The stock traded as low as $3.52 and last traded at $3.57. Approximately 409,255 shares were traded during trading, a decline of 65% from the average daily volume of 1,157,037 shares. The stock had previously closed at $3.79.

CureVac Price Performance

The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The stock has a market cap of $844.03 million, a P/E ratio of 6.85 and a beta of 2.51. The firm’s fifty day moving average price is $3.50 and its 200-day moving average price is $3.21.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its holdings in CureVac by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock worth $162,000 after acquiring an additional 4,425 shares in the last quarter. Signaturefd LLC boosted its stake in shares of CureVac by 26.9% in the third quarter. Signaturefd LLC now owns 27,970 shares of the company’s stock worth $82,000 after acquiring an additional 5,927 shares during the last quarter. Green Alpha Advisors LLC boosted its stake in CureVac by 41.3% during the third quarter. Green Alpha Advisors LLC now owns 27,319 shares of the company’s stock worth $80,000 after buying an additional 7,979 shares during the last quarter. Ballentine Partners LLC lifted its stake in shares of CureVac by 58.6% in the 3rd quarter. Ballentine Partners LLC now owns 22,755 shares of the company’s stock valued at $67,000 after purchasing an additional 8,406 shares during the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of CureVac in the 3rd quarter valued at $30,000. 17.26% of the stock is owned by hedge funds and other institutional investors.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.